BIA 10-2474
BIA 10-2474 is an experimental fatty acid amide hydrolase (FAAH) inhibitor that was developed for the treatment of various medical conditions, including pain and anxiety. The compound gained significant attention due to a clinical trial in France that resulted in severe adverse effects, including one death.
Development[edit | edit source]
BIA 10-2474 was developed by the Portuguese pharmaceutical company Bial. The drug was intended to inhibit the enzyme FAAH, which is involved in the degradation of endocannabinoids such as anandamide. By inhibiting FAAH, BIA 10-2474 was expected to increase the levels of endocannabinoids, potentially providing therapeutic benefits for conditions like chronic pain, anxiety, and neurodegenerative diseases.
Clinical Trial[edit | edit source]
In January 2016, a Phase I clinical trial of BIA 10-2474 was conducted in Rennes, France. The trial was managed by the contract research organization Biotrial. The study aimed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers.
Adverse Effects[edit | edit source]
During the trial, several participants experienced severe neurological symptoms. One participant was declared brain-dead and subsequently died, while others were hospitalized with serious neurological damage. The trial was immediately suspended, and an investigation was launched by French health authorities.
Investigation and Findings[edit | edit source]
The investigation revealed that the adverse effects were likely due to off-target effects of BIA 10-2474. The exact mechanism of toxicity remains unclear, but it was suggested that the drug might have interacted with other enzymes or receptors in the brain, leading to the observed neurotoxicity.
Impact and Aftermath[edit | edit source]
The incident had a significant impact on the field of drug development, particularly concerning the safety of first-in-human trials. It led to increased scrutiny and regulatory changes aimed at improving the safety of early-phase clinical trials.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
